Immunolymphoscintigraphy in breast cancer: Evaluation using 131I- labeled monoclonal antibody B72.3

Lorraine M. Fig, Raya S. Brown, Lisa Von Moll, Henry D. Appelman, Ralph Stevens, Jay Harness, David August, Vernon K. Sondak, Alfred E. Chang, Kenneth R. Zasadny, Susan J. Fisher, Jon W. Johnson, Max S. Wicha, David Colcher, Allen S. Lichter, Richard L. Wahl

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Noninvasive axillary lymph node staging was investigated using [131I]murine monoclonal antibody B72.3 in 16 patients with breast cancer scheduled for axillary dissection. [131I]B72.3 was injected into ipsilateral finger webs or around the breast biopsy. Scintigraphy to 72 h and γ-counting/immunohistochemistry of nodes were performed. Specific antibody uptake (%ID/g) and the ratio of specific:nonspecific antibody uptake were not significantly different in tumor-positive versus tumor-negative nodes, suggesting that [131I]B72.3 is unsuitable to discriminate axillary node tumor involvement.

Original languageEnglish (US)
Pages (from-to)251-260
Number of pages10
JournalNuclear Medicine and Biology
Issue number3
StatePublished - Apr 1998
Externally publishedYes


  • Breast neoplasm
  • Iodine radioisotopes
  • Lymphatic metastasis
  • Monoclonal antibodies
  • Radionuclide imaging

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Immunolymphoscintigraphy in breast cancer: Evaluation using 131I- labeled monoclonal antibody B72.3'. Together they form a unique fingerprint.

Cite this